With the artistic donation of a local artist, hope is rendered in Newport Beach
Cancer survivor Frank Di Bella, right, stands with contemporary abstract artist Leonardo Cruz Melo in front of an artwork created by Cruz Melo at City of Hope Newport Beach on Thursday.
(Kevin Chang / Staff Photographer)
Print
City of Hope Newport Beach is just a couple of blocks away from Fleming’s Steakhouse at Fashion Island.
The two places are more connected than one might think.
Now 40, Leonardo Cruz Melo has been working at Fleming’s since he was a teenager. The bartender is also a contemporary artist, and the restaurant displays his paintings on its walls.
Study: Drug Improves Survival for Kidney Cancer newsmax.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsmax.com Daily Mail and Mail on Sunday newspapers.
email article That s a demand that utterly outstrips the supply that we have. Jim Jackson, PsyD, of Vanderbilt University Medical Center in Nashville, on a study suggesting that many COVID survivors have post-traumatic stress disorder. It s like taking a football and shoving it into a pipe with the diameter of a golf ball. David Nauen, MD, PhD, of Johns Hopkins University in Baltimore, about the unexpected presence of megakaryocytes in the brain capillaries of people who died with COVID-19. This is one of those findings where you can hear it at [the Genitourinary Cancers Symposium] and take it to the clinic on Monday. Sumanta Pal, MD, of City of Hope Comprehensive Cancer Center in Duarte, California, discussing a new option for a rare type of kidney cancer.
email article
Cabozantinib (Cabometyx) came out on top as upfront therapy in metastatic papillary renal cell carcinoma (RCC) in a randomized phase II study.
Treatment with the multikinase inhibitor yielded a median progression-free survival (PFS) of 9.0 months, as compared to 5.6 months with sunitinib (Sutent), which has been the default standard of care in this setting (HR 0.60, 95% CI 0.37-0.97, one-sided
P=0.019), reported Sumanta Pal, MD, of City of Hope Comprehensive Cancer Center in Duarte, California.
Overall response rate was significantly improved with cabozantinib compared with sunitinib (23% vs 4%,
P=0.01), and 5% versus none, respectively, had complete responses, according to findings presented at the virtual Genitourinary Cancers Symposium (GUCS) and published simultaneously in the